

Global Infectious Disease Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

<https://marketpublishers.com/r/G8866095972EN.html>

Date: November 2017

Pages: 211

Price: US\$ 4,400.00 (Single User License)

ID: G8866095972EN

Abstracts

Global Infectious Disease Therapeutics Market:

Global infectious disease therapeutics market estimated to be valued US\$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for infectious disease therapeutics is projected to reach US\$ XX Mn by 2023.

Infectious diseases are caused by organisms, such as bacteria, virus, fungi or parasites. Many organisms live in our body but few of them cause diseases. These infectious diseases transmitted from one individual to other either by direct or indirect contact. The drugs used for the infectious diseases are antibiotics, antiviral, and antiparasitic, among others. Infectious disease therapeutics acts directly on organisms or helps body system to fight infections. Infectious diseases include HIV, malaria, tuberculosis, hepatitis, and influenza, among others.

Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.

Infectious disease therapeutics market segmented based on drug class, disease

indication, and distribution channel

Based on drug class, infectious disease therapeutics market is segmented into

Anti-Bacterial

Anti-Viral

Anti-Parasite

Anti-Fungal

Others

Based on disease indication, infectious disease therapeutics market is segmented into

HIV/AIDS

Influenza

Hepatitis

Malaria

TB

Others

Based on distribution channel, infectious disease therapeutics market is segmented into

Hospital Pharmacy

Retail Pharmacy

Others

Market players focusing on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZeneca's late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in infectious disease therapeutics market. Some of the pipeline anti infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market.

Geographically infectious disease therapeutics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infectives has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry along with government initiative to boost biotechnology sector of the respective country are fuelling the growth of the infectious disease therapeutics market in Asia Pacific region.

Some of the players in infectious disease therapeutics market are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Auritec Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), Sanofi S.A. (France) and Gilead Sciences (U.S.) to name a few.

In July 2017, Gilead's "vosevi" oral tablet was approved by U.S. FDA for treatment of adults with chronic hepatitis C virus

In March 2015, U.S. Food and Drug Administration approved cresemba (isavuconazonium sulfate), a novel antifungal drug for treat adults with invasive aspergillosis and invasive mucormycosis, rare but serious infections

In December 2014, Sanofi Pasteur announces FDA approval of fluzone intradermal

quadrivalent (Influenza Vaccine) for adults.

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor's overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET INTRODUCTION

2.1. Global Infectious Disease Therapeutics Market– Taxonomy

2.2. Global Infectious Disease Therapeutics Market– Definitions

2.2.1. Drug Class

2.2.2. Disease Indication

3. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET DYNAMICS

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Infectious Disease Therapeutics Market Dynamics – Factors Impact Analysis

3.6. Global Infectious Disease Therapeutics Market– Regulations

3.6.1. U.S

3.6.2. Europe

3.6.3. Japan

4. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market Opportunity Analysis

5. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Anti-Bacterial

5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Anti-Viral

- 5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 5.2.3. Market Opportunity Analysis
- 5.3. Anti-Parasite
 - 5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.3.3. Market Opportunity Analysis
- 5.4. Anti-Fungal
 - 5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.4.3. Market Opportunity Analysis
- 5.5. Others
 - 5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 5.5.3. Market Opportunity Analysis

6. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISEASE INDICATION, 2012 - 2016 AND FORECAST, 2017 - 2023

- 6.1. HIV/AIDS
 - 6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.1.3. Market Opportunity Analysis
- 6.2. Influenza
 - 6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.2.3. Market Opportunity Analysis
- 6.3. Hepatitis
 - 6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.3.3. Market Opportunity Analysis
- 6.4. Malaria
 - 6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.4.3. Market Opportunity Analysis
- 6.5. Tuberculosis (TB)
 - 6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
 - 6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
 - 6.5.3. Market Opportunity Analysis

6.6. Others

- 6.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 6.6.3. Market Opportunity Analysis

7. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies

- 7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.1.3. Market Opportunity Analysis

7.2. Retail Pharmacies

- 7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.2.3. Market Opportunity Analysis

7.3. Online Pharmacies

- 7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 7.3.3. Market Opportunity Analysis

8. GLOBAL INFECTIOUS DISEASE THERAPEUTICS MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America

- 8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.1.3. Market Opportunity Analysis

8.2. Europe

- 8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.2.3. Market Opportunity Analysis

8.3. Asia-Pacific

- 8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
- 8.3.3. Market Opportunity Analysis

8.4. Latin America

- 8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
- 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.4.3. Market Opportunity Analysis

8.5. Middle East and Africa

8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)

8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

8.5.3. Market Opportunity Analysis

8.6. Global Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

9.1.1.1. Anti-Bacterial

9.1.1.2. Anti-Viral

9.1.1.3. Anti-Parasite

9.1.1.4. Anti-Fungal

9.1.1.5. Others

9.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.2.1. HIV/AIDS

9.1.2.2. Influenza

9.1.2.3. Hepatitis

9.1.2.4. Malaria

9.1.2.5. TB

9.1.2.6. Others

9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.1.3.1. Hospital Pharmacies

9.1.3.2. Retail Pharmacies

9.1.3.3. Online Pharmacies

9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.1.4.1. U.S.

9.1.4.2. Canada

9.1.5. North America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023

9.1.6. North America Infectious Disease Therapeutics Market Dynamics – Trends

10. EUROPE INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

10.1.1.1. Anti-Bacterial

10.1.1.2. Anti-Viral

10.1.1.3. Anti-Parasite

10.1.1.4. Anti-Fungal

10.1.1.5. Others

10.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.2.1. HIV/AIDS

10.1.2.2. Influenza

10.1.2.3. Hepatitis

10.1.2.4. Malaria

10.1.2.5. TB

10.1.2.6. Others

10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.3.1. Hospital Pharmacies

10.1.3.2. Retail Pharmacies

10.1.3.3. Online Pharmacies

10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.1.4.1. Germany

10.1.4.2. UK

10.1.4.3. France

10.1.4.4. Spain

10.1.4.5. Italy

10.1.4.6. Russia

10.1.4.7. Poland

10.1.4.8. Rest of Europe

10.1.5. Europe Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023

10.1.6. Europe Infectious Disease Therapeutics Market Dynamics – Trends

11. ASIA-PACIFIC INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

11.1.1.1. Anti-Bacterial

11.1.1.2. Anti-Viral

11.1.1.3. Anti-Parasite

11.1.1.4. Anti-Fungal

11.1.1.5. Others

11.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.2.1. HIV/AIDS

11.1.2.2. Influenza

11.1.2.3. Hepatitis

11.1.2.4. Malaria

11.1.2.5. TB

11.1.2.6. Others

11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.1.3.1. Hospital Pharmacies

11.1.3.2. Retail Pharmacies

11.1.3.3. Online Pharmacies

11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),

Y-o-Y Growth (%), and Market Share (%)

11.1.4.1. Japan

11.1.4.2. China

11.1.4.3. India

11.1.4.4. ASEAN

11.1.4.5. Australia & New Zealand

11.1.4.6. Rest of Asia-Pacific

11.1.5. Asia-Pacific Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023

11.1.6. Asia-Pacific Infectious Disease Therapeutics Market Dynamics – Trends

12. LATIN AMERICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

12.1.1.1. Anti-Bacterial

12.1.1.2. Anti-Viral

12.1.1.3. Anti-Parasite

12.1.1.4. Anti-Fungal

12.1.1.5. Others

12.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.2.1. HIV/AIDS

12.1.2.2. Influenza

12.1.2.3. Hepatitis

12.1.2.4. Malaria

12.1.2.5. TB

12.1.2.6. Others

12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.3.1. Hospital Pharmacies

12.1.3.2. Retail Pharmacies

12.1.3.3. Online Pharmacies

12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.1.4.1. Brazil

12.1.4.2. Mexico

12.1.4.3. Argentina

12.1.4.4. Venezuela

12.1.4.5. Rest of Latin America

12.1.5. Latin America Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023

12.1.6. Latin America Infectious Disease Therapeutics Market Dynamics – Trends

13. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.1.1. Anti-Bacterial

13.1.1.2. Anti-Viral

13.1.1.3. Anti-Parasite

13.1.1.4. Anti-Fungal

13.1.1.5. Others

13.1.2. Disease Indication Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.2.1. HIV/AIDS

13.1.2.2. Influenza

13.1.2.3. Hepatitis

13.1.2.4. Malaria

13.1.2.5. TB

13.1.2.6. Others

13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

13.1.3.1. Hospital Pharmacies

13.1.3.2. Retail Pharmacies

13.1.3.3. Online Pharmacies

13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)

13.1.4.1. Gulf Cooperation Council (GCC) Countries

13.1.4.2. Israel

13.1.4.3. South Africa

13.1.4.4. Rest of MEA

13.1.5. MEA Infectious Disease Therapeutics Market- Opportunity Analysis Index - By Drug Class, By Disease Indication, By Distribution Channel, and Country, 2017 – 2023

13.1.6. MEA Infectious Disease Therapeutics Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players

14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)

14.2.1. GlaxoSmithKline Plc (U.K.)

14.2.2. Johnson & Johnson Services, Inc. (U.S.)

14.2.3. Merck & Co, Inc. (U.S.)

14.2.4. Pfizer Inc. (U.S.)

14.2.5. Novartis AG. (Switzerland)

14.2.6. AbbVie Inc. (U.S.)

14.2.7. Astellas Pharma Inc. (Japan)

14.2.8. AstraZeneca (U.K.)

14.2.9. Auritec Pharmaceuticals Inc. (U.S.)

14.2.10. Bayer AG (Germany)

14.2.11. Chimerix Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

I would like to order

Product name: Global Infectious Disease Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: <https://marketpublishers.com/r/G8866095972EN.html>

Price: US\$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G8866095972EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

